Beta

Onconetix, inc.ONCO.US Overview

US StockHealthcare
(No presentation for ONCO)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ONCO AI Insights

ONCO Overall Performance

ONCO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ONCO Recent Performance

3.50%

Onconetix, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ONCO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ONCO's Trend

ONCO Key Information

ONCO Valuation Metrics

ONCO Profile

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Price of ONCO

ONCO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ONCO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.50
PB Ratio
0.03
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
77.62%
Net Margin
-1720.98%
Revenue Growth (YoY)
-67.70%
Profit Growth (YoY)
-40.01%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.50
PB Ratio
0.03
Price-to-FCF
-
Gross Margin
77.62%
Net Margin
-1720.98%
Revenue Growth (YoY)
-67.70%
Profit Growth (YoY)
-40.01%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
  • When is ONCO's latest earnings report released?

    The most recent financial report for Onconetix, inc. (ONCO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ONCO's short-term business performance and financial health. For the latest updates on ONCO's earnings releases, visit this page regularly.

  • What is the operating profit of ONCO?

    According to the latest financial report, Onconetix, inc. (ONCO) reported an Operating Profit of -1.28M with an Operating Margin of -422.06% this period, representing a growth of 95.6% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ONCO's revenue growth?

    In the latest financial report, Onconetix, inc. (ONCO) announced revenue of 303.6K, with a Year-Over-Year growth rate of -57.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ONCO have?

    As of the end of the reporting period, Onconetix, inc. (ONCO) had total debt of 48.77K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ONCO have?

    At the end of the period, Onconetix, inc. (ONCO) held Total Cash and Cash Equivalents of 5.22M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ONCO go with three margins increasing?

    In the latest report, Onconetix, inc. (ONCO) did not achieve the “three margins increasing” benchmark, with a gross margin of 81.6%%, operating margin of -422.06%%, and net margin of 1,867.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ONCO's profit trajectory and future growth potential.

  • Is ONCO's EPS continuing to grow?

    According to the past four quarterly reports, Onconetix, inc. (ONCO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ONCO?

    Onconetix, inc. (ONCO)'s Free Cash Flow (FCF) for the period is -3.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 235.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ONCO?

    The latest valuation data shows Onconetix, inc. (ONCO) has a Price-To-Earnings (PE) ratio of -0.13 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.